Pharmaceutical

EC approves Astellas’ PADCEV for urothelial cancer

The European Commission has authorised Astellas Pharma's PADCEV regimen for the first-line treatment of advanced urothelial cancer.

Aug 29, 2024 - 04:00
EC approves Astellas’ PADCEV for urothelial cancer
The European Commission has authorised Astellas Pharma's PADCEV regimen for the first-line treatment of advanced urothelial cancer.
Read the original article

Tags:

Previous Article

Navigator gains $100m in Series A funding for antibody therapeutics

Next Article

Pfizer launches digital healthcare platform to streamline access

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sweeping bill to fight opioid addiction will be considered by Senate health committee

Sweeping bill to fight opioid addiction will be conside...

Dec 5, 2023

STAT+: Eli Lilly to acquire Versanis in heated race for weight loss drugs

STAT+: Eli Lilly to acquire Versanis in heated race for...

Jul 14, 2023

STAT+: The inside story of how data integrity issues roiled a biotech seen as ‘Moderna 2.0’

STAT+: The inside story of how data integrity issues ro...

Jun 12, 2023